iPS Cells & Regenerative Medicine– category –
-
Editas Medicine Unveils Positive Preclinical Data for Gene Editing Candidate EDIT-401, Demonstrating Significant Reduction in LDL, Lp(a), and ApoB in Non-Human Primates
Investing.com USA Overview Editas Medicine announced positive preclinical data for its gene editing therapeutic candidate EDIT-401, showing significant reductions in LDL cholesterol, lipoprotein(a) (Lp(a)), and apolipoprotein B (ApoB) in... -
FDA Grants RMAT Designation to Cellectis’ Allogeneic CD22 CAR-T Lasme-cel for Relapsed/Refractory B-ALL
Targeted Oncology USA Overview The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Cellectis' lasmecabtagene timgedleucel (lasme-cel; UCART22), an allogeneic CD22-targeting CAR-T cell therapy, for relapsed/re... -
Intellia’s Lonvo-z Achieves 87% Reduction in HAE Attack Rate and 62% Attack-Free Patients in Pivotal Phase 3 In Vivo CRISPR Trial
GlobeNewswire USA Overview Intellia Therapeutics has reported highly positive Phase 3 HAELO clinical trial results for lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene editing therapy for hereditary angioedema (HAE). The therapy a... -
iPS Cells & Regenerative Medicine Weekly Report May 13, 2026
📄 Weekly Report June 13, 2026 (PDF) — Download Weekly Report June 13, 2026 (PDF) — DownloadDownload 🎙 Podcast June 13, 2026 (MP3) — Play & Download iPS_RegenerativeMedicineEnglishPodcast_20260613.mp3Download View Past Weekly Reports→ -
Non-Viral CRISPR/Cas9 HDR Platform Enables Stable Genetic Engineering of Solid Tumor Models, Overcoming Viral Vector Challenges
bioRxiv (Preprint) USA Overview This preprint reports research on a non-viral CRISPR/Cas9 Homology-Directed Repair (HDR) platform for stable genetic engineering of solid tumor models. This approach enables precise genome modification and... -
CombiCult® Screening Platform Establishes Feeder-Free Bioreactor Scalability for iPSC-Derived NK Cell Manufacturing
Frontiers (Preprint) Germany Overview This preprint reports research developing a feeder-free protocol for generating mature, functional iPSC-derived natural killer (iNK) cells using the high-throughput combinatorial screening platform C... -
REPROCELL Develops Hypoimmune iPSC Engineering with AI-Designed CRISPR for Off-the-Shelf Cell Therapies
REPROCELL Japan Overview REPROCELL announced a method to develop hypoimmune iPSCs using AI-designed CRISPR, leveraging its StemEdit gene-editing platform. This approach targets key immune recognition genes like B2M and CIITA to create un... -
Human Continuum Closes Over $5 Million in Seed Round Funding to Advance Exosome-Based Therapeutic Longevity Platform Development
GlobeNewswire (Human Continuum Inc.) USA Overview Human Continuum Inc. successfully completed a $5.13 million seed funding round to accelerate the development of its exosome-based therapeutic and diagnostic platform across longevity, ort... -
Novartis and Orionis Biosciences Enter Strategic Collaboration for Molecular Glue Discovery in Up to $1.4 Billion Deal
BioBucks Biotech BD&L Tracker USA Overview Novartis announced a strategic collaboration with Orionis Biosciences to leverage Orionis' AI-driven "Allo-Glue™" platform across multiple challenging therapeutic targets. The deal includes a $4... -
AmMax Bio Licenses Lonza’s Conjugation and Linker-Payload Technologies for ADC Program AMB-104
The Pharma Letter USA Overview AmMax Bio announced a non-exclusive licensing agreement with Lonza, a leading CDMO, to utilize Lonza's conjugation and linker-payload technologies. This collaboration aims to support the development of AmMa...
